Vista Pharmaceuticals (BOM:524711) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524711 Vista Pharmaceuticals Ltd BOM:524711
48 GF Score
Price ₹6.34
GF Value ₹4.48
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vista Pharmaceuticals Cyclically Adjusted Revenue per Share?

Vista Pharmaceuticals BOM:524711 +5.32% 48 Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus rates BOM:524711 with a GF Score™ of 48/100 and a GF Value™ of ₹4.48 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vista Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vista Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vista Pharmaceuticals was -1.10% per year. The lowest was -1.10% per year. And the median was -1.10% per year.

As of today (2026-08-31), Vista Pharmaceuticals's current stock price is ₹6.34. Vista Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹0.00. Vista Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vista Pharmaceuticals was 1.99. The lowest was 0.84. And the median was 1.35.


Vista Pharmaceuticals  (BOM:524711) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vista Pharmaceuticals was 1.99. The lowest was 0.84. And the median was 1.35.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vista Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Vista Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vista Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vista Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Vista Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 9.57 8.84 7.65 0.00

Vista Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.68 7.58 7.31 0.00 0.00

BOM:524711 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vista Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vista Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:524711
48GF Score
Vista Pharmaceuticals Ltd BOM:524711
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vista Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vista Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Vista Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.442 105.961 3.857
201612 2.462 105.196 3.917
201703 2.049 105.196 3.260
201706 2.724 107.109 4.256
201709 2.292 109.021 3.518
201712 2.514 109.404 3.846
201803 2.342 109.786 3.570
201806 2.282 111.317 3.431
201809 1.909 115.142 2.775
201812 2.362 115.142 3.433
201903 3.246 118.202 4.596
201906 2.278 120.880 3.154
201909 2.412 123.175 3.277
201912 2.220 126.235 2.943
202003 0.241 124.705 0.323
202006 0.000 127.000 0.000
202009 0.125 130.118 0.161
202012 0.104 130.889 0.133
202103 0.129 131.771 0.164
202106 0.000 134.084 0.000
202109 0.078 135.847 0.096
202112 0.029 138.161 0.035
202203 0.000 138.822 0.000
202206 0.000 142.347 0.000
202209 0.000 144.661 0.000
202212 0.000 145.763 0.000
202303 0.209 146.865 0.238
202306 0.477 150.280 0.531
202309 0.790 151.492 0.873
202312 0.345 152.924 0.378
202403 0.668 153.035 0.731
202406 0.314 155.789 0.337
202409 0.410 157.882 0.435
202412 0.415 158.323 0.439
202503 0.525 157.552 0.558
202506 0.259 159.755 0.271
202509 0.237 162.289 0.244
202512 0.427 163.281 0.438
202603 0.000 164.272 0.000
202606 0.000 167.357 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Vista Pharmaceuticals (BOM:524711) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vista Pharmaceuticals and its competitors.
Is Vista Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Vista Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Vista Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vista Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Vista Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vista Pharmaceuticals and its competitors. Vista Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vista Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vista Pharmaceuticals (BOM:524711) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.48, compared to a current price of ₹6.34 — trading 41.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹0.00. Vista Pharmaceuticals' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vista Pharmaceuticals (BOM:524711), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?

Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued. The current stock price of ₹6.34 is trading 41.5% above its estimated GF Value™ of ₹4.48. GuruFocus considers Vista Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524711:

  • Cyclically Adjusted Revenue per Share: ₹0.00
  • GF Value™: ₹4.48 vs. price of ₹6.34 (41.5% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vista Pharmaceuticals Business Description

Address Kakateeya Hills, Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Hyderabad, TG, IND, 500033
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
48GF Score

Get the complete analysis for BOM:524711

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6.34
Price
₹4.48
GF Value